阿托伐他汀治疗冠心病患者高脂血症临床观察

目的 观察阿托伐他汀(立普妥)治疗冠心病伴高脂血症的临床效果.方法 选择2009年1月至2011年3月冠心病伴高脂血症患者120例为观察对象,随机分为观察组60例和对照组60例,两组均按冠心病伴高脂血症常规内科治疗,观察组加用阿托伐他汀10 mg,1次/天口服,疗程12周,统计分析治疗前后两组血脂水平变化及心绞痛,心律失常发作次数、心力衰竭及脑卒中事件,不良反应等情况.结果 观察组治疗后总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)及甘油三酯(triacylgly cerol,TG)水平均较治疗前下降显著,而高密度脂蛋白胆固醇(high-density lipoprotein-cholesterol,HDL-C)水平升高明显(P＜0.01),而对照组治疗前后TC、LDL-C及TG水平差异无统计学意义(P＞0.05)；观察组治疗期间平均发生心绞痛、心律失常及心力衰竭加重例数显著低于对照组,同时无脑卒中事件发生(P＜0.01)；观察组不良反应发生率略高于对照组,但差异无统计学意义(P＞0.05).结论 阿托伐他汀能快速降低冠心病患者血脂水平,降低心脑血管事件发生,缓解冠心病患者临床症状,安全性好,可于临床广泛应用.

Clinical observation of atorvastatin for treating hyperlipidemia in patients with coronary heart disease

Objective To observe the clinical effect of atorvastatin in treating coronary heart disease complicating hyperlipidemia.Methods 120 cases of coronary heart disease(CHD) complicating hyperlipidemia from Jan.2009 to Mar.2011 were selected as the observation subjects and divided into the observation group(60 cases) and the control group(60 cases).Both groups received the same conventional medical treatment.The observation group was given oral atorvastatin 10mg,once daily.After 12 weeks treatment,the change of blood fat,angina pectoris,arrhythmia,heart failure,stroke and adverse reactions were statistically analyzed and compared between 2 groups.Results The levels of TC,LDL-C and TG after treatment in the observation group were obviously decreased than before treatment,while the HDL-C level was obviously increased(P<0.01).But the levels of TC,LDL-C and TG in the control group had no significant difference before and after treatment(P>0.05).The cases of angina pectoris,arrhythmia and heart failure exacerbation during treatment in the observation group were significantly less than those in the control groups,at the same time no stroke events occurred(P<0.01).The adverse reactions in the observation group were slightly higher than those in the control group without statistical significance(P>0.05).Conclusion Atorvastatin can rapidly lower the blood lipid level in the patients with CHD,reduce the occurrence of cardiocerebralvascular events and relieve the clinical symptoms with better security,which can be generally used in clinic.